Surrozen, Inc. (NASDAQ:SRZN) Given Consensus Rating of "Moderate Buy" by Brokerages

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $45.00.

Several brokerages have weighed in on SRZN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research note on Friday, July 17th. Zacks Research raised shares of Surrozen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. William Blair assumed coverage on shares of Surrozen in a report on Thursday. They issued an "outperform" rating and a $51.00 price objective on the stock. Finally, HC Wainwright restated a "buy" rating and issued a $44.00 price objective on shares of Surrozen in a report on Monday, August 10th.

Surrozen Price Performance

Shares of Surrozen stock opened at $23.99 on Monday. Surrozen has a 52 week low of $10.73 and a 52 week high of $35.00. The business's fifty day simple moving average is $23.11 and its 200-day simple moving average is $25.65. The firm has a market cap of $278.52 million, a PE ratio of -0.59 and a beta of 0.52.

Surrozen (NASDAQ:SRZN - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.29) by $0.88. The business had revenue of $5.00 million for the quarter, compared to analyst estimates of $0.47 million. As a group, equities analysts expect that Surrozen will post -7.62 earnings per share for the current year.

Insider Transactions at Surrozen

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the business's stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total value of $6,906,250.00. Following the sale, the insider owned 574,047 shares of the company's stock, valued at $12,198,498.75. The trade was a 36.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 31.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Surrozen

Institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company's stock valued at $34,000 after buying an additional 500 shares during the period. Persistent Asset Partners Ltd purchased a new position in Surrozen during the 4th quarter valued at about $99,000. Citadel Advisors LLC boosted its holdings in Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock valued at $179,000 after acquiring an additional 3,424 shares during the period. Marshall Wace LLP acquired a new position in Surrozen in the 4th quarter valued at about $247,000. Finally, Geode Capital Management LLC increased its stake in Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after purchasing an additional 5,702 shares during the period. 66.57% of the stock is owned by institutional investors and hedge funds.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source